clinical trial · NCT05922436
a Study Evaluating the Safety and Efficacy of Clevidipine for Patients Who With Hypertensive Emergency and Sub-emergency
Qilu Pharmaceutical (Hainan) Co., Ltd.·phase3·unknown·n = 378
Hypertensive EmergencyQLG2071Cleviprex®
brief summary
A Multicentre, Randomized, Double-blind, Parallel Design Phase III Study to Evaluate the efficacy and safety of QLG2071 Versus Cleviprex® in the Treatment of Hypertensive Emergency and Sub-emergency
started
Jul 15, 2023
primary completion
May 24, 2024
completion
May 25, 2024
last updated
Jun 28, 2023
detailed description
This is a multicenter, randomized, double-blind, active-compared Phase III clinical study to evaluate the efficacy and safety of clevidipine butyrate injectable emulsion in the treatment of Hypertensive Emergency and Sub-emergency. The Cleviprex® will be chosen as the positive controlled medicine with the same usage of the test drug
official title
A Multicentre, Randomized, Double-blind, Parallel Design Phase III Study to Evaluate the Efficacy and Safety of Intravenous QLG2071 Versus Cleviprex® for Patients With Hypertensive Emergency and Sub-emergency
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol